June 3 (Reuters) - Pharma Mar SA PHMR.MC :
- THERAPEUTIC GOODS ADMINISTRATION (TGA) GRANTS "PROVISIONAL APPROVAL PATHWAY" FOR LURBINECTEDIN IN RELAPSED SMALL CELL LUNG CANCER (SCLC) IN AUSTRALIA
- THIS DESIGNATION ALLOWS A FASTER APPROVAL OF DRUGS FOR SERIOUS CONDITIONS THAT FILL AN UNMET MEDICAL NEED
- DATA FROM PHASE II STUDY OF LURBINECTEDIN SHOWED 35% OVERALL RESPONSE RATE IN SECOND-LINE PATIENTS, AND MEDIAN OVERALL SURVIVAL OF 9.3 MONTHS
- Forums
- Science & Medicine
- News: Pharma Mar: TGA Grants "Provisional Approval Pathway" For Lurbinectedin In SCLC In Australia
News: Pharma Mar: TGA Grants "Provisional Approval Pathway" For Lurbinectedin In SCLC In Australia
Featured News
Featured News
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online